Xeris Pharmaceuticals | XERS - Assets


Xeris Pharmaceuticals reported $411.9M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Celltrion KRW 768.81B 9.37B Mar/2026
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 1.21B 33.61M Jun/2026
Divis Laboratories Ltd INR 200.33B 18.82B Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Kangmei Pharma CNY 13.07B 239.31M Jun/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Organigram Holdings CAD 521.31M 9.36M Mar/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pharma Mar EUR 393.6M 8.34M Jun/2026
Qiagen NV USD 5.89B 107.14M Jun/2026
Sartorius EUR 9.6B 270.6M Jun/2026
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
Tilray USD 2.1B 15.95M Sep/2025
Zealand Pharma A/S 15.3B 647.8M Mar/2026
Zz Pientze Pharmaceu CNY 18.51B 129.02M Jun/2026